News | March 16, 2009

NEVO, XIENCE DES Will Go Head-to-Head in New Clinical Trial

March 16, 2009 - Cordis Corp. said today it plans to launch a global, head-to-head, randomized clinical trial called NEVO II, which will compare the NEVO sirolimus-eluting coronary stent to the XIENCE V everolimus-eluting coronary stent.

Cordis and Conor Medsystems LLC are sponsors of the study.

NEVO is the first and only drug-eluting stent utilizing a unique reservoir (RES) technology, which Cordis acquired from Conor Medsystems in 2007. It incorporates hundreds of small reservoirs, each acting as a depot into which drug-polymer compositions are loaded. This revolutionary design allows drug delivery from a stent with a surface that is 75 percent bare metal upon insertion and becomes fully bare metal following drug delivery and polymer bioresorption in approximately three months.

NEVO contains the same drug, sirolimus, as the CYPHER sirolimus-eluting coronary stent, which has now been used in more than 3 million people worldwide. The data supporting the safety and efficacy of Sirolimus in coronary applications is now available out to six years, and this body of clinical evidence is completely unmatched by any other anti-restenotic stent coating.

“We continue to be very enthusiastic about NEVO and believe it represents the most significant advance in the drug-eluting stent market since we launched the CYPHER Stent,” said Campbell Rogers, M.D., FACC, chief scientific officer and global head, research and development, Cordis. “We also understand that in a rapidly evolving competitive and regulatory environment, it is incumbent on companies to show how a new product compares to a more recently approved product in the category, which is what we are doing with this new trial.”

NEVO II will be a global, randomized, non-inferiority trial of approximately 2,000 patients with coronary artery disease. Results from this trial will provide long-term data in support of a pre-market application (PMA) with the FDA. The company plans to meet with regulatory authorities soon to finalize the design for this trial.

In the U.S., NEVO III will serve as the pivotal trial for a PMA submission to the FDA. NEVO III is designed as a non-randomized, single-arm trial evaluating clinical outcomes in approximately 1,000 patients.

The six-month trial results from NEVO RES I will be presented at the EuroPCR conference in Barcelona, Spain in May. This randomized trial compares NEVO to the TAXUS Stent and involves 394 patients. Results from this trial will support a design dossier submission for CE mark approval in Europe and in other countries that accept CE mark designation.

The previously announced NEVO RES II trial, a non-randomized, single-arm registry of approximately 1,000 patients, has been canceled. The company will complete the protocol-defined follow-up for patients enrolled in this trial to date.

In other drug-eluting stent news from Cordis, the company announced plans to initiate a trial in the U.S. of approximately 2,000 patients that will compare clinical outcomes in a broad range of patients receiving dual antiplatelet therapy (DAPT) for 12 months versus 30 months after receiving a CYPHER stent. This trial will contribute to the company’s involvement in a broader DAPT clinical program that is being led by the FDA.

In order to focus on realizing the full potential of NEVO, Cordis noted that it will cease development of the CYPHER ELITE sirolimus-eluting coronary stent program. Approximately 700 patients in the U.S. have been enrolled in the clinical trial for this product and they will continue to be followed for five years, the duration of the follow-up period in the protocol.

For more information:,

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init